← Human Trials & Peer-Reviewed Studies
Supplement study update for Reach Out: a multi-arm randomized trial of behavioral interventions for hypertension initiated in the emergency department: Reach Out Cognition.
Plain-language guide to PMID 34819115 (2021): randomized controlled trial of Copper (Supplement).
Key Facts
- PMID
- 34819115
- Journal
- Trials
- Year
- 2021
- Study type
- Randomized Controlled Trial
- Authors
- Skolarus LE et al. (7 authors)
- DOI
- 10.1186/s13063-021-05806-4
- Registered trial
- NCT03422718
What This Study Did, in Plain Language
What Was Tested
Researchers studied Copper (Supplement) in this randomized controlled trial publication.
The original study protocol was published in June 2020.
Here, the researchers describe the updated protocol, including a supplemental study, Reach Out Cognition.
Who Took Part
Reach Out Cognition includes remote enrollment and follow-up assessments.
Participants will be Reach Out participants who complete their 12-month outcome assessments and opt to continue in the cohort study.
How the Study Was Run
The researchers set it up as a randomized study.
The participants were allocated by chance, so the Copper (Supplement) group and the comparison group should start out alike.
Reach Out Cognition extends Reach Out data collection past the current 12 months to 15 and 18 months.
Blood pressure will be measured using Bluetooth-enabled self-measured blood pressure monitoring devices, and cognition will be measured using digital self-administered cognitive assessments at 12, 15, and 18 months.
What Was Measured
Reach Out Cognition is a remote study that will assess the acceptability, feasibility, and satisfaction of digital, self-administered cognitive assessments and Bluetooth-enabled, self-measured blood pressure monitoring in the Reach Out population.
PubMed files the paper under topics including Cognition, Cohort Studies, Emergency Service, Hospital, Hypertension and Text Messaging.
The authors tagged it with the keywords Emergency Medicine, Health Equity and Multiphase Optimization Strategy.
What This Means in Plain Language
The paper is a randomized study of Copper (Supplement).
Results are reported in around 2 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2021 (Trials), a journal based in England.
More context: the Copper (Supplement) compound page, all human trials.
Our Notes on the Compound
Copper (Supplement): The active site of cytochrome c oxidase is described as containing copper ions that are essential for electron transfer.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.